These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23784368)

  • 1. Capsule commentary on Shahinian et al.: Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.
    Penson DF
    J Gen Intern Med; 2013 Nov; 28(11):1494. PubMed ID: 23784368
    [No Abstract]   [Full Text] [Related]  

  • 2. Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.
    Shahinian VB; Kuo YF
    J Gen Intern Med; 2013 Nov; 28(11):1440-6. PubMed ID: 23670565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
    Berruti A; Dogliotti L; Terrone C; Cerutti S; Isaia G; Tarabuzzi R; Reimondo G; Mari M; Ardissone P; De Luca S; Fasolis G; Fontana D; Rossetti SR; Angeli A;
    J Urol; 2002 Jun; 167(6):2361-7; discussion 2367. PubMed ID: 11992038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for osteoporosis in men receiving androgen deprivation therapy.
    Alibhai SM; Yun L; Cheung AM; Paszat L
    JAMA; 2012 Jan; 307(3):255-6. PubMed ID: 22253389
    [No Abstract]   [Full Text] [Related]  

  • 6. Differing Effects of Zoledronic Acid on Bone Microarchitecture and Bone Mineral Density in Men Receiving Androgen Deprivation Therapy: A Randomized Controlled Trial.
    Cheung AS; Hoermann R; Ghasem-Zadeh A; Tinson AJ; Ly V; Milevski SV; Joon DL; Zajac JD; Seeman E; Grossmann M
    J Bone Miner Res; 2020 Oct; 35(10):1871-1880. PubMed ID: 32542695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.
    Khriguian J; Tsui JMG; Vaughan R; Kucharczyk MJ; Nabid A; Bettahar R; Vincent L; Martin AG; Jolicoeur M; Yassa M; Barkati M; Igidbashian L; Bahoric B; Archambault R; Villeneuve H; Mohiuddin M; Niazi T
    J Urol; 2021 Jun; 205(6):1648-1654. PubMed ID: 33577365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.
    Bruder JM; Ma JZ; Wing N; Basler J; Katselnik D
    J Clin Densitom; 2006; 9(4):431-7. PubMed ID: 17097529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of androgen deprivation therapy on periodontal disease in men with prostate cancer.
    Famili P; Cauley JA; Greenspan SL
    J Urol; 2007 Mar; 177(3):921-4. PubMed ID: 17296376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
    Smith MR
    Cancer; 2003 Feb; 97(3 Suppl):789-95. PubMed ID: 12548577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy.
    Lee CE; Leslie WD; Lau YK
    BMC Cancer; 2012 Mar; 12():103. PubMed ID: 22436542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
    Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
    N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy.
    Greenspan SL; Wagner J; Nelson JB; Perera S; Britton C; Resnick NM
    J Bone Miner Res; 2013 Feb; 28(2):325-32. PubMed ID: 22991066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
    Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-reported exercise and bone mineral density in prostate cancer patients receiving androgen deprivation therapy.
    Mennen-Winchell LJ; Grigoriev V; Alpert P; Dos Santos H; Tonstad S
    J Am Assoc Nurse Pract; 2014 Jan; 26(1):40-48. PubMed ID: 24170604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
    Magno C; Anastasi G; Morabito N; Gaudio A; Maisano D; Franchina F; Galì A; Frisina N; Melloni D
    Eur Urol; 2005 May; 47(5):575-80; discussion 580-1. PubMed ID: 15826746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
    Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
    Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.